Title
Category
Credits
Event date
Cost
- S.U.D
- 1.00 AAFP Prescribed
- 1.00 AMA PRA Category 1 Credit™
- 1.00 AOA Category 2-A
$0.00
This activity is part of CAFP's California Residency Program Collaborative around improving education, outreach and treatment for patients with substance use disorder disease, including stimulants and opioids, with a focus on medication assisted treatment options.Learning Objective:At the end of this session, learners should be able to:
- S.U.D
- 0.50 AAFP Prescribed
- 0.50 AMA PRA Category 1 Credit™
- 0.50 AOA Category 2-A
$0.00
This activity is part of CAFP's California Residency Program Collaborative around improving education, outreach and treatment for patients with substance use disorder disease, including stimulants and opioids, with a focus on medication assisted treatment options. Learning Objectives:At the end of this session, participants should be able to:
- S.U.D
- Women's Health
- 0.75 AAFP Prescribed
- 0.75 AMA PRA Category 1 Credit™
- 0.75 AOA Category 2-A
$0.00
This activity is part of CAFP's California Residency Program Collaborative around improving education, outreach and treatment for patients with substance use disorder disease, including stimulants and opioids, with a focus on medication assisted treatment options.Learning Objectives:After this course, participants should be able to:
- S.U.D
- 0.75 AAFP Prescribed
- 0.75 AMA PRA Category 1 Credit™
- 0.75 AOA Category 2-A
$0.00
This activity is part of CAFP's California Residency Program Collaborative around improving education, outreach and treatment for patients with substance use disorder disease, including stimulants and opioids, with a focus on medication assisted treatment options. Learning Objectives:At the end of this session, learners should be able to:
- S.U.D
- 0.50 AAFP Prescribed
- 0.50 AMA PRA Category 1 Credit™
- 0.50 AOA Category 2-A
$0.00
This activity is part of CAFP's California Residency Program Collaborative around improving education, outreach and treatment for patients with substance use disorder disease, including stimulants and opioids, with a focus on medication assisted treatment options.Learning Objective:At the end of this session, learners should be able to:
- 1.00 AAFP Prescribed
$0.00
Despite the successes demonstrated by Accountable Care Organizations (ACOs) over the last decade, health disparities remain a critical and ever-growing challenge. ACOs have the potential to advance health equity, but without intentionality and guardrails in place, they are also in a position to worsen existing health disparities. For ACOs to truly succeed in improving patient health outcomes for all, it's imperative that health equity is kept at the forefront of value-based care efforts. Learning Objective:At the end of this session, learners should be able to:
- 3.00 AAFP Prescribed
$0.00
The 2023 All Member Advocacy Meeting (AMAM) focused on health equity and provided tools and information to help develop family physicians trained and dedicated to being effective advocates for their patients and specialty. This course contains the recordings from the following sessions: Keynote - Born to be an Advocate, Evaluating Policy with an Equity Lens, and Other Advocacy Avenues: Running for Office, Serving on Advisory Committees.Learning Objective:At the end of this session, learners should be able to:
- S.U.D
- 1.00 AAFP Prescribed
$0.00
Join Family Physician Rebecca Trotsky-Sirr and Sergeant Brian Gunsolley for a discussion of how patients are obtaining Fentanyl and other synthetic opioids and how physicians can help their patients recognize and understand the dangers of non-prescribed medication as well as encourage the use of reversal agents. In addition, resources will be provided to encourage more use of Medication Assisted Treatment.Learning Objectives:At the end of this session, learners should be able to:
- Trauma-Informed Care
- 20.00 AAFP Prescribed
- 20.00 AMA PRA Category 1 Credit™
$0.00
Adverse Childhood Experiences (or ACEs) are associated with some of the most common, serious, and intractable health conditions facing our patients. Toxic stress from ACEs such as poverty, violence, and emotional or physical abuse can cause wear and tear on all body systems. In fact, ACEs are associated with increased risk for heart disease, cancer, accidents, respiratory disease, stroke, diabetes, kidney disease, and suicide.
- Diabetes
- 1.00 AAFP Prescribed
- 1.00 AOA Category 2-A
$0.00
This interactive, case-based activity provides education on the clinical characteristics of the GLP-1 RAs, how they differ from each other, and the rationale and guidance for their use with patients with Type 2 Diabetes (T2D). Participants will encounter clinical case scenarios on personalizing treatment with GLP-1 RAs, taking into account patient characteristics and preferences, adherence, and management of side effects.Learning Objectives:At the end of this session, learners should be able to: